| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/30/2001 | US20010018071 Oral 2-methyl-thieno-benzodiazepine formulation |
| 08/30/2001 | US20010018070 Extending the duration of drug release within the stomach during the fed mode |
| 08/30/2001 | US20010018069 Oral administration of fast-dispersing/disintegrating forumulation of dopamine agonist, antiemetic, opioid antagonist, testosterone, and flavored carrier; pregastric absorption; side effect reduction |
| 08/30/2001 | US20010018065 Administering drugs comprised of antibiotic, carrier, and oligosaccharide-support which binds and removes shiga-like toxins from gastrointestinal tract; Escherichia; enterotoxins; antidiarrhetics |
| 08/30/2001 | US20010018060 Use of particular fatty substances which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter |
| 08/30/2001 | US20010018059 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 08/30/2001 | US20010018045 Antiperspirant compositions |
| 08/30/2001 | DE10008948A1 L-Ascorbinsäure und NaCl als Carrier zur Hormon-No-und Enzymsynthese L-ascorbic acid and NaCl as a carrier for hormone-No-and enzyme synthesis |
| 08/30/2001 | DE10008329A1 New aminosulfonyl-biphenyl derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or angina pectoris |
| 08/30/2001 | DE10008279A1 Synergistic medicinal or health-promoting food additive composition, comprising lactose, inulin and/or oligofructose, calcium salt and Bifidus bacteria, having e.g. immunostimulant and digestion improving action |
| 08/30/2001 | DE10008274A1 Substituierte 8,8a-Dihydro-3aH-indeno[1,2-d]thiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted 8,8a-dihydro-3aH-indeno [1,2-d] thiazoles, process for their preparation and their use as medicaments |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2671940A1 Identification of partial agonists of the a2a adenosine receptor |
| 08/30/2001 | CA2657986A1 Substituted piperazine compounds |
| 08/30/2001 | CA2406871A1 Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 08/30/2001 | CA2402114A1 Sulfur containing compounds |
| 08/30/2001 | CA2401356A1 Combination drug |
| 08/30/2001 | CA2401226A1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 08/30/2001 | CA2401063A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 08/30/2001 | CA2401036A1 Pyridinylimidazoles |
| 08/30/2001 | CA2401031A1 Tlp peptides and dna sequences coding the same |
| 08/30/2001 | CA2401030A1 Use of 2-phenylene diamine derivatives for the treatment of infections |
| 08/30/2001 | CA2401016A1 Scytonemin and methods of using thereof |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | CA2400953A1 Orally administrable acid stable anti-ulcer benzimidazole derivatives |
| 08/30/2001 | CA2400952A1 Method of purifying a fermentation broth |
| 08/30/2001 | CA2400923A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400896A1 Novel compositions and uses of dictyostatin compounds |
| 08/30/2001 | CA2400892A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same |
| 08/30/2001 | CA2400875A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400819A1 Method for producing quinolonecarboxylic acids and intermediates thereof |
| 08/30/2001 | CA2400797A1 Therapeutic agents |
| 08/30/2001 | CA2400708A1 Methods and compositions for improving sleep |
| 08/30/2001 | CA2400698A1 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents |
| 08/30/2001 | CA2400694A1 Thiazolium compounds and treatments of disorders associated with protein aging |
| 08/30/2001 | CA2400692A1 Substituted 8, 8a-dihydro-3ah-indeno[1,2-d]thiazoles, a method for their production and their use as medicaments |
| 08/30/2001 | CA2400691A1 Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease |
| 08/30/2001 | CA2400682A1 Method for the preparation of citalopram |
| 08/30/2001 | CA2400661A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | CA2400606A1 New phosphodiesterase type 7b |
| 08/30/2001 | CA2400491A1 Compositions and methods for treatment of epilepsy |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2399999A1 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | CA2399550A1 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 08/30/2001 | CA2399442A1 New drug combinations |
| 08/30/2001 | CA2399418A1 Metalloproteinase inhibitors for the treatment of respiratory diseases |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2399255A1 Caspase activated prodrugs therapy |
| 08/30/2001 | CA2399036A1 Improvement of implantation rate |
| 08/30/2001 | CA2399018A1 Aminosulfonylbiphenyl derivatives |
| 08/30/2001 | CA2397874A1 Use of pramipexole for the treatment of addictive disorders |
| 08/30/2001 | CA2397558A1 Dosing regimen |
| 08/30/2001 | CA2397234A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2396971A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 08/30/2001 | CA2396960A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2394088A1 Method for transdermal or intradermal delivery of molecules |
| 08/30/2001 | CA2368447A1 Small molecule modulators of g protein-coupled receptor six |
| 08/30/2001 | CA2368382A1 Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient |
| 08/30/2001 | CA2368366A1 Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient |
| 08/30/2001 | CA2365606A1 Medicament for prevention or treatment of various diseases involving an increase in eosinophils chymase inhibitor as effective ingredient |
| 08/29/2001 | EP1127884A1 Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
| 08/29/2001 | EP1127883A2 Oxamides as IMPDH inhibitors |
| 08/29/2001 | EP1127882A1 Tetrazole compounds as thyroid receptor ligands |
| 08/29/2001 | EP1127880A2 Phenylacetic acid derivatives substituted by a heterocycle and their use as A-II antagonists and as inhibitors of smooth muscle cell proliferation |
| 08/29/2001 | EP1127878A1 3,4 - substituted pyrazoles for the treatment of inflammation |
| 08/29/2001 | EP1127871A1 New esters derived from substituted phenyl-cyclohexyl compounds |
| 08/29/2001 | EP1127869A1 Novel compounds and medicinal use thereof |
| 08/29/2001 | EP1127582A2 Use of cladribine on a stent to prevent restenosis |
| 08/29/2001 | EP1127580A2 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 08/29/2001 | EP1127576A1 Uses of NM23-polypeptides in skin and intestinal disorders |
| 08/29/2001 | EP1127575A2 Ocular tissue regeneration inducer |
| 08/29/2001 | EP1127574A1 Use of chitinous materials for inhibiting cellular nitric oxide production |
| 08/29/2001 | EP1127573A1 Compostitions and methods for treating osteoporosis |
| 08/29/2001 | EP1127572A2 Use of flavones for treating cycloxygenase-2 mediated diseases |
| 08/29/2001 | EP1127571A1 Use of sertraline to treat post traumatic stress disorder |
| 08/29/2001 | EP1127570A2 Production process for polymeric micelle composition charged therein with drug |
| 08/29/2001 | EP1127567A2 Aqueous dispersions of water insoluble organic sunscreens |
| 08/29/2001 | EP1127152A1 A method of recombination and agents useful for same |
| 08/29/2001 | EP1127150A2 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| 08/29/2001 | EP1127137A1 Lps with reduced toxicity from genetically modified gram negative bacteria |
| 08/29/2001 | EP1127133A2 Polypeptide mediating cell permeability |
| 08/29/2001 | EP1127131A2 Connective tissue growth factor (ctgf) and methods of use |
| 08/29/2001 | EP1127115A1 Antisense oligomer |
| 08/29/2001 | EP1127110A1 Modified exosomes and uses |
| 08/29/2001 | EP1127074A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 08/29/2001 | EP1127065A2 $i(chlamydia) antigens and corresponding dna fragments and uses thereof |
| 08/29/2001 | EP1127059A1 Imidazonaphthyridines |
| 08/29/2001 | EP1127058A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 08/29/2001 | EP1127057A1 Naphthyridine compounds and thier azaisosteric analogues as antibacterials |
| 08/29/2001 | EP1127054A1 Novel inhibitors of impdh enzyme |
| 08/29/2001 | EP1127052A1 Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| 08/29/2001 | EP1127051A2 Tricyclic pyrazole derivatives |
| 08/29/2001 | EP1127045A2 Use of triphenylbutene derivatives for the treatment of neurological disorders |
| 08/29/2001 | EP1126884A2 Radiodense compositions |
| 08/29/2001 | EP1126880A2 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 08/29/2001 | EP1126871A2 Combination therapy with vip antagonist |
| 08/29/2001 | EP1126870A2 Use of vegf-c or vegf-d gene or protein to prevent restenosis |